Novel Molecular Therapies Appendix
appendix
Download the Appendix as a PDF.
Articles in this issue
Acute Myeloid Leukemia in the Elderly: A Unique Disease
Adjuvant Therapy for Early Lung Cancer: Reflections and Perspectives
What Defines an 'Elderly Patient With AML'?
Thirty Years Later: We've Only Just Begun
Management of Early-Stage Lung Cancer: Past, Present, and Future Adjuvant Trials
Progress With a Purpose: Eliminating Suffering and Death Due to Cancer
Teleoncology Extends Access to Quality Cancer Care
Does This Woman Have Gestational Trophoblastic Disease?
Managing Acute Myeloid Leukemia in the Elderly
Prevention of Colorectal Cancer: An Emerging Role for High-Dose Vitamin D Supplementation?
Commentary (Knoop): Understanding Novel Molecular Therapies
Understanding Novel Molecular Therapies
Toxicity of Targeted Therapy
Recognizing and Managing Side Effects Associated With Novel Targeted Therapies:
Novel Molecular Therapies Appendix
Recent Videos
Related Content
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Aiman Waheed, MBBS;Muhammad Numan Saleem, MBBS;Yash Shah, MD;Muhammad Hamza Gul, MBBS, MD;Helai Hussaini, MD;Abdul Baseer Wardak, MBBS
December 6th 2024Article
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
Clayton K. Oakley, DO, MS, MA;Amulya Yellala, MD;Sunil Tulpule, MD;Robin High, MA;Apar Kishor Ganti, MD;Alissa S. Marr, MD
December 5th 2024Article
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
